长春瑞滨联合顺铂与多西他赛联合顺铂治疗晚期老年非小细胞肺癌临床对比研究  

Clinical observation of original chemotherapy for advanced non-small cell lung cancer between changchun swiss bank combined with cisplatin regimen and docetaxel combined with cisplatin regimen

作　　者：安志洁[1] 郭成业[1] 陈梅慧 庄安士[1] 王大志[1] 李德爱[2] 

机构地区：[1]山东省青岛市市立医院肿瘤科,山东青岛266071 [2]山东省青岛市市立医院药学部,山东青岛266071

出　　处：《中国医刊》2015年第12期37-39,共3页Chinese Journal of Medicine

基　　金：山东省青岛市医疗卫生优秀人才培养项目资助(青卫科教字2014[2])

摘　　要：目的观察长春瑞滨联合顺铂(NP方案)和多西他赛联合顺铂(TP方案)一线治疗老年晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的疗效和不良反应。方法 140例晚期NSCLC完全随机法分成NP组和TP组,入组的每例患者接受至少2个周期以上的NP或TP同样方案的化疗,比较两组化疗方案的近期疗效和不良反应。结果 NP和TP两组近期疗效的有效率分别为39.71%和37.50%,两组中位生存期分别为8.5个月和8.3个月,两者之间差异无显著性。不良反应方面,主要是骨髓抑制和消化道反应等,对症处理均可恢复或耐受。结论 NP和TP两种化疗方案对晚期NSCLC均有较好的临床疗效,化疗不良反应虽有所不同,但均可耐受或恢复。故NP和TP两种化疗方案均可作为老年晚期NSCLC的一线治疗方案。Objective To investigate the efficacy and toxicity of the changchun swiss bank combined with cisplatin（ NP regimen） and docetaxel combined with cisplatin（ GP regimen） on advanced non-small cell lung cancer.Method 140 patients with advanced non-small cell lung cancer were divided into the NP and TP group randomly.Intravenous chemotherapy and preponderated over 2 cycles had been accepted. A clinical observation on short term effectiveness and adverse effects were carried out in two groups. Result The short term effective rate for advanced non-small cell lung cancer in NP group and TP group was 39. 71% and 37. 50% respectively. The median survival time was 8. 5 months and 8. 3 months respectively. The short term effectiveness in two groups had no statistically significant difference. In the adverse effects of treatment,the major cytotoxicity was thrombocytopenia in NP group and leukopenia in TP group,but they were tolerable. Conclusion Both NP regimen and TP regimen on advanced non-small cell lung cancer show more effectiveness. The side effects of the two regimens are different but all adverse reactions are tolerable. They could become the original chemotherapy in advanced non-small cell lung cancer.

关 键 词：非小细胞肺癌 化疗 临床对比研究 

分 类 号：R734.2[医药卫生—肿瘤]